New combo therapy may cut need for frequent eye shots in macular degeneration
NCT ID NCT00527475
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding a light-based treatment (photodynamic therapy) to the standard drug ranibizumab could reduce the number of eye injections needed for wet macular degeneration. Sixty adults over age 50 with the condition took part. The goal was to see if the combination worked as well as ranibizumab alone while requiring fewer injections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Associated Retinal Consultants
Ann Arbor, Michigan, 49301, United States
-
California Retina Consultants & Research Foundation
Santa Barbara, California, 93103, United States
-
Texas Retina Associates
Arlington, Texas, 76012, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Longer-Lasting eye injection could cut treatment visits for macular disease
- Can a new eye injection save vision in wet AMD?
- Eye injection aims to tame leading causes of blindness
- Higher-Dose eye injection may help wet AMD patients who Didn't respond to standard treatments
- New eye drug aims to save sight in wet AMD
- Could stem cells restore sight in damaged eyes?